REGULATORY

• LDP Pharma Project Team to Compile Roadmap Proposals after Industry Hearings
  April 17, 2026

• DPJ Leader to Urge Drug Price Hikes, “Freeze” on Off-Year Revisions
  April 17, 2026

• War-Linked Supply Impact Cases Climb to 34 as Japan Steps Up Response
  April 17, 2026

• Meiji Pharma Chair Prods Drug Price Hikes as War Drives Up Costs: Diet
  April 17, 2026

• Japan Eases Documentation Requirements for Excipients Listed in Foreign Pharmacopoeias
  April 17, 2026

• Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
  April 16, 2026

• MHLW to Set Criteria for Exemptions under OTC-Like Drug Charge Scheme
  April 16, 2026

• MHLW Taps Kawabata to Lead Drug Discovery Support Office
  April 15, 2026

• MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
  April 15, 2026

• Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
  April 14, 2026

• LDP, Ishin to Explore Role of Private Insurance in Reform Talks
  April 14, 2026

• Middle East War Hitting API Air Freight, Trade Group Warns
  April 13, 2026

• Japan’s 19th Pharmacopoeia Revision Takes Effect
  April 13, 2026

• Voranigo and More Meds Missing from April Listing Slate; Servier Plans Packaging Change
  April 10, 2026

• Health Insurance Reform Bill Enters Diet Debate; OTC-Like Drug Charges in Focus
  April 10, 2026

• CEPI Seeks Continued Technology, Funding Ties with Japan
  April 10, 2026

• Dialysis Tubing and Medical Device Makers Fret over Long-Term Supply Risks
  April 10, 2026

• Japan Moves to Bypass Wholesalers in Fuel Supply to Hospitals
  April 10, 2026

• Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
  April 9, 2026

• Briviact Set for Price Cut with CEA Adjustment Rate of 0.1
  April 9, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »